Stirling reports positive preliminary trial results

By Melissa Trudinger
Tuesday, 30 November, 2004

Stirling Products (ASX: STI) has reported that preliminary results from the trials of its lead product ST810 (R-salbutamol) in pigs indicate significantly higher potency than expected, with economic viability at the lowest dose tested.

Final results from the trial, which was conducted in the US by the USDA's Swine Research Unit, will be released early in 2005. The trial was designed to measure physiological and behavioural parameters including weight gain, feed conversion, increase in lean meat and decrease in fat content.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd